We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$426M
AUM Growth
-$8.17M
Cap. Flow
-$21.9M
Cap. Flow %
-5.15%
Top 10 Hldgs %
33.1%
Holding
137
New
22
Increased
24
Reduced
54
Closed
27

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$7.8M
2
BIIB icon
Biogen
BIIB
+$7.48M
3
FOLD
Amicus Therapeutics
FOLD
+$6.39M
4
CYTK icon
Cytokinetics
CYTK
+$6.32M
5
TRVI icon
Trevi Therapeutics
TRVI
+$4.98M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$10.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.03M
3
NICE icon
Nice
NICE
+$5.13M
4
MRUS
Merus
MRUS
+$4.48M
5
SNY icon
Sanofi
SNY
+$4.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.73%
2 Technology 17.1%
3 Consumer Discretionary 1.67%
4 Utilities 1.53%
5 Communication Services 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UBER icon
51
Uber
UBER
$145B
$2.8M 0.66%
30,000
– –
SRPT icon
52
Sarepta Therapeutics
SRPT
$1.65B
$2.72M 0.64%
159,323
+1,392
+0.9% +$59.4K
CAMT icon
53
Camtek
CAMT
$6.16B
$2.7M 0.63%
31,976
+8,890
+39% +$600K
ESLT icon
54
Elbit Systems
ESLT
$36.6B
$2.7M 0.63%
+6,000
New +$2.43M
PANW icon
55
Palo Alto Networks
PANW
$259B
$2.68M 0.63%
+13,114
New +$2.44M
WIX icon
56
WIX.com
WIX
$2.62B
$2.68M 0.63%
16,931
+8,131
+92% +$1.31M
AMGN icon
57
Amgen
AMGN
$210B
$2.65M 0.62%
9,500
-500
-5% -$142K
SEDG icon
58
SolarEdge
SEDG
$2.45B
$2.61M 0.61%
127,966
-181,250
-59% -$3M
ELVN icon
59
Enliven Therapeutics
ELVN
$3.77B
$2.58M 0.61%
128,515
+16,772
+15% +$318K
SRPT icon
60
CALL
Sarepta Therapeutics
SRPT
$1.65B
$2.56M 0.6%
+150,000
New +$6.4M
SKYE icon
61
Skye Bioscience
SKYE
$22.1M
$2.25M 0.53%
538,434
-937,919
-64% -$1.94M
BBIO icon
62
PUT
BridgeBio Pharma
BBIO
$16.6B
$2.15M 0.51%
+49,900
New +$1.81M
DYN icon
63
Dyne Therapeutics
DYN
$4.17B
$2.11M 0.49%
221,416
-107,846
-33% -$1.19M
PFE icon
64
Pfizer
PFE
$144B
$2.08M 0.49%
86,000
-4,000
-4% -$93.3K
BHVN icon
65
Biohaven
BHVN
$2.04B
$2.05M 0.48%
145,372
+45,588
+46% +$812K
SRRK icon
66
Scholar Rock
SRRK
$5.9B
$2.04M 0.48%
57,497
-20,696
-26% -$650K
ETNB
67
DELISTED
89bio
ETNB
$2.02M 0.47%
205,675
-412,668
-67% -$3.42M
GPCR icon
68
Structure Therapeutics
GPCR
$3.37B
$1.99M 0.47%
95,931
+11,931
+14% +$262K
JANX icon
69
Janux Therapeutics
JANX
$917M
$1.98M 0.47%
85,840
-40,000
-32% -$1.05M
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
$1.98M 0.46%
114,346
-67,000
-37% -$1.24M
CRM icon
71
Salesforce
CRM
$156B
$1.85M 0.44%
6,800
-2,300
-25% -$615K
ENGN icon
72
enGene Therapeutics
ENGN
$121M
$1.84M 0.43%
504,409
-23,956
-5% -$89.9K
CYBR
73
DELISTED
CyberArk
CYBR
$1.63M 0.38%
+4,000
New +$1.46M
MRVL icon
74
Marvell Technology
MRVL
$154B
$1.45M 0.34%
18,730
+3,660
+24% +$228K
COGT icon
75
CALL
Cogent Biosciences
COGT
$6.83B
$1.44M 0.34%
+200,000
New +$1.11M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return

Sphera Funds Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sphera Funds Management held 137 positions worth $426M, down 1.9% from $434M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $21.9M in Q2 2025, closing 27 positions and reducing 54 holdings. Its most notable exit was Nice, an estimated $5.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Amicus Therapeutics worth $5.68M.

  • Sphera Funds Management's largest Q2 2025 buy was Amicus Therapeutics: 990,718 shares worth $5.68M.
  • Sphera Funds Management added most to Tower Semiconductor in Q2 2025, an estimated $7.8M increase.
  • Sphera Funds Management's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Nice in Q2 2025, selling an estimated $5.13M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $426M portfolio in Q2 2025.
  • Sphera Funds Management opened 22 new positions and closed 27 in Q2 2025.
  • Sphera Funds Management's portfolio value fell 1.9% quarter-over-quarter to $426M.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.